No Data
Sector Update: Health Care
Lipocine Granted FDA Fast Track Designation for LPCN 1148
FDA Grants Fast Track Designation To Lipocine's LPCN 1148 For Treating Sarcopenia In Patients With Decompensated Cirrhosis, Targeting First-In-Class Status With Novel Mechanism Of Action
Express News | FDA Grants Fast Track Designation to Lipocine for Lpcn 1148 as a Treatment for Sarcopenia in Patients With Decompensated Cirrhosis
FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients With Decompensated Cirrhosis
Lipocine Announces The Publication And Discussion Of A Manuscript "Oral LPCN 1148 Improves Sarcopenia And Hepatic Encephalopathy In Male Patients With Cirrhosis: A Randomized, Placebo-controlled Phase 2 Trial" In The Journal Hepatology And Discussion...
No Data
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
